Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Lung Neoplasms 9Glioblastoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Brenner Tumor 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Oligodendroglioma 3Carcinoma 3Astrocytoma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mouth Neoplasms 2Medulloblastoma 2

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Papillary renal cell carcinoma, sporadic × Disulfides × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡